Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

858 Therapeutics raises $60 million

by Ryan Cross
September 24, 2021 | A version of this story appeared in Volume 99, Issue 35

 

858 Therapeutics has launched with $60 million in series A financing to develop small-molecule cancer drugs. The San Diego-based start-up also acquired Gotham Therapeutics for an undisclosed sum. Gotham launched in 2018 to develop drugs based on epitranscriptomics, the study of chemical modifications to RNA. Gotham’s lead program is a drug that targets METTL3, an RNA-modifying enzyme that is elevated in some cancers. 858 hopes to advance that program into clinical trials by 2023.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.